Business
Press Release (Revised) Dec 15 2023
Cipla Limited has informed the Exchange regarding a revised press release dated December 15, 2023, titled "Revised Press Release - This is further to the press release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised press release on the said matter.
About this update from Cipla Ltd
Cipla Limited has informed the Exchange regarding a revised press release dated December 15, 2023, titled "Revised Press Release - This is further to the press release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised press release on the said matter. View Attachment
More from Cipla Ltd
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US
September 4, 2026
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in...
September 3, 2026